Articles On Race Oncology (ASX:RAC)

Returns in the ASX healthcare basket were fairly robust throughout 2021. Sector earnings saw a return to pre-COVID levels as patient and service volumes began to normalise as well. The S&P/ASX 200 Health Care Index (ASX: XHJ) has clim...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

“The number of applications reflects enthusiasm for the significant potential of our lead drug Zantrene and this enables us to implement our planned clinical and drug development plans across the three-pillar program,” managing director and...

Race Oncology (ASX: RAC) is closing out 2021 with an extra $29.7 million in the bank after completing a heavily oversubscribed share purchase plan that saw almost $44 million in applications. Under the share purchase plan, eligible existing...

Race Oncology (RAC) raises $29.7 million in an oversubscribed share purchase plan The company received applications totalling almost $44 million from 2340 shareholders, with the funds to be used to accelerate the company’s clinical and dev...

The Race Oncology Ltd (ASX: RAC) share price is climbing today on the back of the company’s latest capital raise. During morning trade, the pharmaceutical company’s shares are up 3.64% to $3.42 apiece. What did the company announce? Invest...

After identifying its heart protective effects, Race Oncology (ASX: RAC) has extended the collaboration with the University of Newcastle for its Zantrene (bisantrene dihydrochloride) anti-cancer drug. Earlier this week, Race revealed precli...

This strategically important collaboration will underpin a cardio-protective Phase 2b clinical trial in cancer patients at high risk of anthracycline-induced heart damage, which is expected to begin treating patients in late 2022.

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

Clinical stage RNA focused company targeting multiple cancer indications with estimated annual oncology revenues of >US$2.6 billion

“Zantrene is the first anti-cancer agent that we have found to exhibit a cardioprotective profile while being synergistically effective as an anti-cancer treatment," says University of Newcastle associate professor Doan Ngo.

Specialty pharmaceutical company Race Oncology (ASX: RAC) has found its lead candidate Zantrene (bisantrene dihydrochloride) is able to protect heart muscles from cell death caused by chemotherapy drug carfilzomib. Results from a preclinica...

Race Oncology (RAC) confirms Zantrene can protect heart muscle cells from carfilzomib-induced cell death while improving the carfilzomib-mediated killing of cancer cells Associate Professor Doan Ngo says Zantrene showed it can salvage over...

Precision oncology company Race Oncology (ASX: RAC) is looking to raise capital to enable the execution of its expanded business strategy and to progress the clinical program of its anti-cancer drug Zantrene following a recent breakthrough...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

The ASX drifted sideways on Wednesday, as uncertainty continues to linger around the outlook for monetary policy, interest rates and broader market liquidity following the reappointment of Jerome Powell as US Fed chair. While the ASX 200 tr...

Investors are selling off shares in precision oncology company Race Oncology Ltd (ASX: RAC) after a flurry of market sensitive announcements yesterday. At the time of writing, shares in the RNA focused company are down around 12.47% at $3...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has just dropped into the red. At the time of writing, the benchmark index is down slightly to 7,408.9 points. Four ASX shares that are falling more than most today are listed below....

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Highlights As per experts, the global cancer drug market is likely to accelerate in the upcoming years due to the widespread prevalence of cancer.  The increased focus of the healthcare sector on cancer research has been a critical fac...

The Australian bourse recouped most of yesterday’s losses despite tech stocks dropping again, this time by 3.49%. The ASX 200 rose 0.78%, closing at 7,411 points, with the gains driven by the resources and energy sectors, which gained 2.3%...

Cancer biotech Race Oncology is tapping its base of loyal retail shareholders for a fresh capital raise of up to $30 million,

The company said this is the first time a drug has demonstrated the ability to both target the cancer and protect the heart from anthracycline damage.

Shares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) jumped higher today and finished 13% in the green. Investors bid up the Race Oncology share price following study readouts for its lead drug candidate, Zantrene, in...

Race Oncology’s drug Zantrene shown to protect human heart muscle cells from anthracycline-induced chemotherapy death. Anthracycline’s are the most used and effective anti-cancer drugs, yet they can cause serious heart damage. The preclin...

The ASX 200 Health Index (XHJ) is down by 0.35% at the time of writing, compared to the broader index which is down by 0.80%. A private fund owned by the Forrest family, Tattarang, has invested $5m or 7.3% stake in cannabis company, Emyria...

Interim research results has found Race Oncology’s (RAC) Zantrene drug can protect heart muscles from anthracycline induced cell death while boost the killing of breast cancer cells Anthracyclines are one of the most effective anti-cancer...

Race Oncology (RAC) joins forces with the University of Wollongong (UOW) for a preclinical evaluation of new formulations of its Zantrene anti-cancer drug The collaboration provides Race with access to UOW’s lab and expertise to rapidly ad...

The ASX 200 Health Index (XHJ) is up by 0.57% at the time of writing, compared to the broader index which is up by 0.03%. The US FDA has cleared Pharmaxis (ASX:PXS)’s Investigational New Drug application (IND) for a trial of its lead drug,...

Shares in Australian pharmaceutical company Race Oncology Ltd (ASX: RAC) are up 4% from the open to now trade at $3.41 apiece. This follows an intraday high of $3.52. Race Oncology shares are on the move despite there being no market-sensi...

Race Oncology (RAC) reports a slight decrease in cash and equivalents to $8.94 million as of 30 September 2021, down from $9.32 million as of 30 June 2021 The minimal decrease in cash reserves, according to Race, reflects option exercise p...

The Race Oncology Ltd (ASX: RAC) share price is edging lower today despite a positive development by the pharmaceutical company. At the time of writing, Race Oncology shares are fetching for $3.23, down 2.12%. This means over the past mont...

Just like yesterday the ASX rallied for most of the day but retreated in the afternoon and today closed in the red. The ASX 200 was down 0.08% at 7,375 points. Another difference from yesterday was tech was the best sector gaining 1.7% whil...

The Race Oncology Ltd (ASX: RAC) share price has been seesawing today and is now at $3.17. That’s a 0.32% gain on the previous closing price. Race shares have been as high as $3.19 and as low as $3.08 so far today. This comes after an anno...

Race Oncology (RAC) is granted its sixth US patent for its cancer drug, Zantrene, valid until July 2034 The company says the new patent provides Race with further protection around uses of Zantrene, allowing it to further expand its therap...

Race Oncology (ASX:RAC) has announced it has been issued a new patent from the US Patent and Trademarks Office for its cancer drug, Zantrene (bisantrene dihydrochloride).

Highlights  Magellan Financial Group shares dropped over 7% after it reported a drop in its FUM in September. Shares of Endeavour fell over 1% on exit of its CEO Bruce Mathieson Jr. Pilbara Minerals shares surged over 5% on robust qua...

The Race Oncology Ltd (ASX: RAC) share price has been a positive performer on Wednesday. In morning trade, the precision oncology company’s shares are up 3.5% to $3.30. Why is the Race Oncology share price rising today? Investors have been...

Race Oncology (ASX:RAC) has shared interim results from its collaborative preclinical melanoma research program with the University of Newcastle.

The ASX finished September on a solid note but not enough to avoid the worst month since March 2020. The ASX 200 closed at 7,332 points which was 1.88% higher than yesterday but nearly 3% lower than it started the month at. However it is up...

Zantrene® at low concentrations kills high FTO producing melanoma cancer cells Sensitivity to Zantrene® correlates with FTO levels, where high FTO producing cells show up to 60x greater sensitivity than low FTO producing cells Results ar...

The Race Oncology Ltd (ASX: RAC) share price jumped out of the starting blocks today, shooting up 7% to a high of $3.66. This was after the biopharma company announced a key update on results from one of its research programs. The Race Onc...

Our new business model is to research, analyse, and invest in up and coming small cap ASX-listed biotech stocks that we believe have a high chance of success. We then share our research and commentary along our investment journey with our r...

The Race Oncology Ltd (ASX: RAC) share price has soared into the green this past month, and now trades at $3.50 apiece. Whereas the S&P/ASX 200 Health Care Index (XHJ) has gained a paltry 0.85% in the last month of trading, Race Oncol...

In the past fortnight there were nearly four dozen directors on the ASX who bought or sold shares in trades above $100,000. Code Company Director Change Date Volume $ What ODY Odyssey Gold Levi Mochkin Buy 18 August 2,0...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...